In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results CagriSema vs Tirzepatide: Weight Loss Results in REDEFINE 4 Trial Paramesh Shamanna posted on the topic LinkedIn What is the pipeline for future medications for obesity? International Journal of Obesity Obesity pharmacotherapy in older adults: a narrative review of evidence International Journal of Obesity Cagrilintide, an amylin analogue, is a promising medication for weight loss by enhancing satiety, delaying gastric emptying, and suppressing appetite. In my patients, I have also seen increased